RESUMO
Sulfur and nitrogen mustards are internationally banned vesicants listed as Schedule 1 chemical agents in the Chemical Weapons Convention. These compounds are highly reactive electrophiles that form stable adducts to a variety of available amino acid residues on proteins upon exposure. We present a quantitative exposure assay that simultaneously measures agent specific protein adducts to cysteine for sulfur mustard (HD) and three nitrogen mustards (HN1, HN2, and HN3). Proteinase K was added to a serum or plasma sample to digest protein adducts and form the target analyte, the blister agent bound to the tripeptide cysteine-proline-phenylalanine (CPF). The mustard adducted-tripeptide was purified by solid phase extraction and analyzed using isotope dilution LC-MS/MS. Product ion structures were identified using high-resolution product ion scan data for HD-CPF, HN1-CPF, HN2-CPF, and HN3-CPF. Thorough matrix comparison, analyte recovery, ruggedness, and stability studies were incorporated during method validation to produce a robust method. The method demonstrated long term-stability, precision (RSDâ¯<â¯15%), and intra- and inter-day accuraciesâ¯>â¯85% across the reportable range of 3.00-200â¯ng/mL for each analyte. Compared to previously published assays, this method quantitates both sulfur and nitrogen mustard exposure biomarkers, requires only 10⯵L of sample volume, and can use either a liquid sample or dried sample spot.
Assuntos
Exposição Ambiental/análise , Compostos de Mostarda/sangue , Albumina Sérica/química , Biomarcadores/sangue , Biomarcadores/química , Cromatografia Líquida de Alta Pressão , Cisteína/sangue , Cisteína/química , Humanos , Compostos de Mostarda/química , Reprodutibilidade dos Testes , Albumina Sérica/análise , Espectrometria de Massas em TandemRESUMO
A bioanalytical method for the determination of the anticancer drug chlorambucil (Leukeran) and its phenyl acetic acid mustard metabolite in human serum and plasma is described. Automated solid-phase extraction of the analytes is carried out with C18 sorbent packed in a 96 well format microtitre plate using a robotic sample processor. The extracts are analysed by isocratic reversed-phase liquid chromatography using pneumatically and thermally assisted electrospray ionisation (TurboIonspray) with selected reaction monitoring. The method is specific and sensitive, with a range of 4-800 ng/ml in human serum and plasma for both parent drug and metabolite (sample volume 200 microl). The method is accurate and precise with intra-assay and inter-assay precision (C.V.) of <15% and bias <15% for both analytes. The automated extraction procedure is significantly faster than manual sample pre-treatment methods, a batch of 96 samples is extracted in 50 min allowing for faster sample turnaround. The method has been used to provide pharmacokinetic support to biocomparability studies of Leukeran following single doses of oral tablet formulations.
Assuntos
Antineoplásicos/sangue , Clorambucila/sangue , Cromatografia Líquida/métodos , Espectrometria de Massas/métodos , Análise de Variância , Antineoplásicos/metabolismo , Automação , Clorambucila/metabolismo , Humanos , Compostos de Mostarda/sangue , Compostos de Mostarda/metabolismoRESUMO
The plasma pharmacokinetics of 1-(2-chloroethyl)-3-(2,6-dioxo-1-piperidyl)1-nitrosourea (PCNU) were determined in ambulatory rats and in patients receiving PCNU chemotherapy in Phase 1 and II studies. After derivativization to the methyl carbamate, both rat and human PCNU plasma levels were measured by gas chromatography-mass spectrometry. Comparison of the tolerated dose levels and pharmacokinetics of PCNU to the values determined for 1,3-bis(2-chloroethyl)-1-nitrosourea in humans indicated that PCNU has a lower plasma drug area under the curve at equitoxic doses. We conclude that PCNU may show less clinical efficacy than 1,3-bis(2-chloroethyl)-1-nitrosourea in the treatment of solid tumors.
Assuntos
Compostos de Nitrosoureia/sangue , Animais , Carmustina/sangue , Carmustina/uso terapêutico , Ensaios Clínicos como Assunto , Avaliação de Medicamentos , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Cinética , Compostos de Mostarda/sangue , Compostos de Mostarda/uso terapêutico , Compostos de Mostarda/toxicidade , Neoplasias/tratamento farmacológico , Compostos de Nitrosoureia/uso terapêutico , Compostos de Nitrosoureia/toxicidade , RatosRESUMO
Through specific examples, the versatility of HSLC in clinical and pharmacological studies has been demonstrated. These examples are not intended to restrict the vision of the reader, like that of the author, but on the contrary, it is hoped that those not yet familiar with the usefulness of HSLC will gain perspective concerning this technique in their own fields of interest. The virtually unlimited ability to separate cellular metabolites (or other organic compounds for that matter) by HSLC is a reality at this time; however, development of more selective, sensitive means of detection and positive identification of eluting components is needed, similar to that gained by coupling mass spectrometry with gas chromatography.